China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

By South China Morning Post | Created at 2026-08-27 02:26:58 | Updated at 2026-09-20 04:50:21 3 weeks ago

Select Speed

0.8x0.9x1.0x1.1x1.2x1.5x1.75x

Read Entire Article
  1. Homepage
  2. Asia
  3. China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

Related

The cooling trap: how Asia’s air conditioners are making heatwaves worse

The cooling trap: how Asia’s air conditioners are making hea...

50 minutes ago
Reporter’s note: two Delhis, one weekend – when the world came to dinner

Reporter’s note: two Delhis, one weekend – when the world ca...

50 minutes ago
Shark sighting leads to unexpected popularity of Busan port in South Korea

Shark sighting leads to unexpected popularity of Busan port ...

1 hour ago
Bear gets on fishing boat, dozes off before falling into sea in Japan’s Miyagi Prefecture

Bear gets on fishing boat, dozes off before falling into sea...

1 hour ago

Notice

Any news articles older than one week will be automatically deleted.

Donate us by clicking here.

Popular

Netanyahu deliberately enabled Hamas October 7 attack – victims

Netanyahu deliberately enabled Hamas October 7 attack – vict...

3 days ago
Forget low-calorie food, Chinese youth turn to tasteless, chewy snacks to lose weight

Forget low-calorie food, Chinese youth turn to tasteless, ch...

6 days ago
189 Children Found, Over 12,000 Arrested in Memphis Task Force Operations

189 Children Found, Over 12,000 Arrested in Memphis Task For...

3 days ago
Global Economy Briefing — September 17, 2026

Global Economy Briefing — September 17, 2026

2 days ago
Anthropic CEO Says ‘We Owe It To Humanity To Try’ To Prevent An AI Swarm From Taking Over The Internet

Anthropic CEO Says ‘We Owe It To Humanity To Try’ To Prevent...

6 days ago
About Us · About Sources · Contact Us · Request a News Source · RSS · Donate · List of News Sources ·

© DevEvil News 2026. All rights are reserved, All content on this website, including articles, images, and logos sourced from external RSS feeds, as well as original content produced by DevEvil News, is protected by copyright law.